menu
    • menu
    [{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Elektrofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0.79000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.79000000000000004,"dosageForm":"Intratumoral Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Legend Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Intravenous Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":1.7,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Intravenous Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.98999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.98999999999999999,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Fate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":3.1000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":3.1000000000000001,"dosageForm":"Oral","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Genocea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"11","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Undisclosed","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"}]

    Find Clinical Drug Pipeline Developments & Deals by JANSSEN BIOTECH

    Menu

    JANSSEN BIOTECH

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Simcha Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Licenses Decoy-Resistant IL-18 for Cell Therapy

                            Details : Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary DR-18 for a set number of programs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Simcha Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Elektrofi

                            Deal Size : $793.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Elektrofi and Janssen Biotech Collaborate to Develop Formulation Technology Programs

                            Details : The collaboration focuses on developing an at-home subcutaneous version of a lead oncology asset and up to four additional targets using Elektrofi's formulation technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $18.0 million

                            March 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Elektrofi

                            Deal Size : $793.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Foundation Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

                            Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

                            Product Name : Akeega

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 07, 2024

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Foundation Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : LegoChem Biosciences

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

                            Details : Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84, a Trop2 directed ADC which is currently being investigated for advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : $100.0 million

                            December 26, 2023

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : LegoChem Biosciences

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icotrokinra

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $987.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ...

                            Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $50.0 million

                            December 13, 2023

                            Lead Product(s) : Icotrokinra

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $987.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocytogen Announces RenLite® Licensing Agreement with Janssen

                            Details : Janssen will use Biocytogen’s proprietary RenLite® platform to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug tar...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prizloncabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cellular Biomedicine Group

                            Deal Size : $245.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next G...

                            Details : Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 05, 2023

                            Lead Product(s) : Prizloncabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cellular Biomedicine Group

                            Deal Size : $245.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aprocitentan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Idorsia Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idorsia Submits European Marketing Authorisation Application for Aprocitentan for The Treatment of Patients wi...

                            Details : ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.

                            Product Name : Tryvio

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Aprocitentan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Idorsia Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icotrokinra

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $990.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ...

                            Details : The collaboration aims for the co-development and commercialization of JNJ-2113, a novel, first and only oral IL-23 receptor antagonist peptide, in patients with moderate-to-severe psoriasis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $50.0 million

                            January 11, 2023

                            Lead Product(s) : Icotrokinra

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $990.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Lava Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Mov...

                            Details : Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Lava Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth